News

benzinga_article
2025.11.25 19:45
BriaCell Therapeutics shares are trading higher after the company announced that it will highlight Phase 2 safety and efficacy signals and biomarker findings in both the Phase 2 and the pivotal Phase 3 studies at 2025 SABCS.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer